Mycophenolate mofetil FAQ

Cellcept (mycophenolate mofetil) side effect?

Hi, I had a liver transplant 12 years ago due to PSC and been on Tacrolimus (prograf) since. no problem with the medication. recently kidneys got really bad and now I am in hospital. dr are planning to change my Tacrolimus to cellcept but I am so upset. 12 years I was with tacrolimus and I trust it so much. how can I change it and feel comfortable. I am worry about all the unknown side effect of it. is it any WEIGHT GAINE associated with it? its only cellcept and NOT combine with steroid. can some one please help me and answer my question?

'Multi-target' Immune Therapy Improves Outcomes Of Severe Lupus Nephritis ScienceDaily (July 7, 2008) — A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a new report. In our study, multi-target therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects, comments Dr. Lei-Shi Li of the Research Institute of Nephrology of Jinling Hospital, Nanjing University School of Medicine in Nanjing,China. The study included 40 patients with severe lupus nephritis. Lupus nephritis is inflammation of the kidneys occurring in patients with the immune system disease systemic lupus erythematosus (SLE). All patients had class V+IV disease, meaning widespread inflammation and decreasing function of the kidneys. This is a severe form of lupus nephritis that is traditionally treated with a single immunosuppressant drug, but the efficacy is very poor, says Dr. Li. We considered that, since the impact of severe SLE on the kidney involves various parts of the immune system, it is necessary to treat the different immune targets with a combination of immunosuppressant drugs. One group of patients received this multi-target therapy, consisting of the immunosuppressant drugs tacrolimus and mycophenolate mofetil--commonly used as anti-rejection drugs in transplant patients--plus a steroid. The other group received standard treatment with a single immunosuppressant drug (cyclophosphamide). The complete remission rate, with recovery of normal kidney function, was about four times higher among patients receiving the three-drug combination. For patients receiving multi-target therapy, the complete remission rate reached 65 percent at nine months, versus only 15 percent under traditional therapy, says Dr. Li. Some patients in both groups had partial remission, with some return of kidney function. Overall, 95 percent of patients in the multi-target therapy group had partial or complete remission, compared to 55 percent with single-drug therapy. The rate of most adverse effects was also lower with multi-target therapy. Systemic lupus erythematosus is an autoimmune disorder, in which the immune system attacks healthy organs and tissues. By reducing immune system activity, treatment with immunosuppressant drugs has improved most outcomes for patients with SLE. However, class V+IV lupus nephritis continues to be a major problem--it has a poor response to traditional treatments and can lead to permanent kidney damage. The prognosis is very poor, so it is important for us to develop a new regimen for the treatment of this type of lupus nephritis, says Dr. Li. Using a combination of drugs that affect different immune targets, multi-target therapy improves the chances of remission for patients with severe lupus nephritis. The therapeutic effect of our multi-target therapy is apparently superior to traditional therapy for inducing complete remission of Class V+IV lupus nephritis, and also bears good tolerance under relatively lower dosages, Dr. Li adds. The authors stress that their study is only preliminary. The study includes a small group of patients from a single hospital, with a relatively short follow-up time. Larger randomized trials with longer follow-up are required.

I would like to know if any one else out there has the cross over bit as there is little or no literature on this as it is relatively rare, or so I am told! Is there anything I can be advised of that might help. Meds are Ursodeoxycholic Acid, Mycophenolate Mofetil. Please this is a serious question and I would like a little respect on this one. thank you x Thankyou for that. I have looked at the web site. I have multiple connective tissue disorders but nothing mentions about liver overlap. I will email them. thanks again

Does Cellcept (mycophenolate mofetil) affect blood presure?

Why does Alonzo Mourning dont wear it? is he taking a special medicine? Im taking CELLCEPT(mycophenolate mofetil), NEORAL(cyclosporine) and PREDNISONE(5mg)

Mycophenolate mofetil news

Cadila receives US FDA nod for mktg Mycophenolate Mofetil - Hindu

Cadila receives US FDA nod for mktg Mycophenolate Mofetil Hindu, India Mumbai (PTI): Cadila Healthcare, the flagship company of Zydus Cadila group, on Tuesday said it has received the US regulatory approval to market its drug Mycophenolate Mofetil , which is used to suppress immune system in organ transplant. ZYDUS RECEIVES USFDA NOD FOR MARKETING MYCOPHENOLATE MOFETIL Trading Markets (press release) Zydus receives USFDA approval for marketing Myiris.com Zydus gets nod from USFDA to market Risperidone tablet Myiris.